As reported in the SOLAR‐1 trial, whether PIK3CA mutation is detected in plasma ctDNA or in cancer tissue, patients can benefit remarkably from alpelisib and fulvestrant combination therapy [31]. The gene discussed is PIK3CA; the disease is cancer.